Neuroprotective effects of ginsenosides Rh1 and Rg2 on neuronal cells

Chinese Medicine

Volumn 6, Issue , 2011, Pages

  Li, Xiao Fan ^a   Lui, Cathy N ^a   Jiang, Zhi Hong ^a   Ken, Yung K ^a  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

GINSENOSIDE; GINSENOSIDE RH 2; GINSENOSIDES RH1; LACTATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE; OXIDOPAMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL DENSITY; CELL GROWTH; CELL STRAIN; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; NERVE CELL DIFFERENTIATION; NEURITE; NEUROPROTECTION; NONHUMAN; RAT; WESTERN BLOTTING;

EID: 79955988875     PISSN: None     EISSN: 17498546     Source Type: Journal    
DOI: 10.1186/1749-8546-6-19     Document Type: Article

References (59)

1. Warner TT, Schapira AH. Genetic and environmental factors in the cause of Parkinson's disease. Ann Neurol 2003, 53(Suppl 3):16-25.
2. Davie CA. A review of Parkinson's disease. Br Med Bull 2008, 86:109-127. 10.1093/bmb/ldn013, 18398010.
3. Hanrott K, Gudmunsen L, O'Neill MJ, Wonnacott S. 6-Hydroxydopamine-induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase Cδ. J Biol Chem 2006, 281:5373-5382.
4. Linert W, Herlinger E, Jameson RF, Kienzl E, Jellinger K, Youdim MB. Dopamine, 6-hydroxydopamine, iron, and dioxygen--their mutual interactions and possible implication in the development of Parkinson's disease. Biochim Biophys Acta 1996, 1316:160-168.
5. Napolitano A, Crescenzi O, Pezzella A, Prota G. Generation of the neurotoxin 6-hydroxydopamine by peroxidase/H2O2 oxidation of dopamine. J Med Chem 1995, 38:917-922. 10.1021/jm00006a010, 7699708.
6. Soto-Otero R, Méndez-Alvarez E, Hermida-Ameijeiras A, Muñoz-Patiño AM, Labandeira-Garcia JL. Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease. J Neurochem 2000, 74:1605-1612.
7. Blum D, Torch S, Nissou MF, Benabid AL, Verna JM. Extracellular toxicity of 6-hydroxydopamine on PC12 cells. Neurosci Lett 2000, 283:193-196. 10.1016/S0304-3940(00)00948-4, 10754220.
8. Ge KL, Chen WF, Xie JX, Wong MS. Ginsenoside Rg1 protects against 6-OHDA-induced toxicity in MES23.5 cells via Akt and ERK signaling pathways. J Ethnopharmacol 2010, 127:118-123. 10.1016/j.jep.2009.09.038, 19799986.
9. Li Z, Hu Y, Zhu Q, Zhu J. Neurotrophin-3 reduces apoptosis induced by 6-OHDA in PC12 cells through Akt signaling pathway. Int J Dev Neurosci 2008, 26:635-640. 10.1016/j.ijdevneu.2008.03.009, 18462913.
10. Rodriguez-Blanco J, Martín V, Herrera F, García-Santos G, Antolín I, Rodriguez C. Intracellular signaling pathways involved in post-mitotic dopaminergic PC12 cell death induced by 6-hydroxydopamine. J Neurochem 2008, 107:127-140. 10.1111/j.1471-4159.2008.05588.x, 18665912.
11. Rausch WD, Liu S, Gille G, Radad K. Neuroprotective effects of ginsenosides. Acta Neurobiol Exp (Wars) 2006, 66:369-375.
12. Hasegawa H. Proof of the mysterious efficacy of ginseng: basic and clinical trials: metabolic activation of ginsenoside: deglycosylation by intestinal bacteria and esterification with fatty acid. J Pharmacol Sci 2004, 95:153-157. 10.1254/jphs.FMJ04001X4, 15215638.
13. Chen CF, Chiou WF, Zhang JT. Comparison of the pharmacological effects of Panax ginseng and Panax quinquefolium. Acta Pharmacol Sin 2008, 29:1103-1108. 10.1111/j.1745-7254.2008.00868.x, 18718179.
14. Rudakewich M, Ba F, Benishin CG. Neurotrophic and neuroprotective actions of ginsenosides Rb(1) and Rg(1). Planta Med 2001, 67:533-537. 10.1055/s-2001-16488, 11509974.
15. Chen XC, Fang F, Zhu YG, Chen LM, Zhou YC, Chen Y. Protective effect of ginsenoside Rg1 on MPP+-induced apoptosis in SHSY5Y cells. J Neural Transm 2003, 110:835-845. 10.1007/s00702-003-0005-y, 12898340.
16. Chen XC, Zhou YC, Chen Y, Zhu YG, Fang F, Chen LM. Ginsenoside Rg1 reduces MPTP-induced substantia nigra neuron loss by suppressing oxidative stress. Acta Pharmacol Sin 2005, 26:56-62. 10.1111/j.1745-7254.2005.00019.x, 15659115.
17. Hwang YP, Jeong HG. Ginsenoside Rb1 protects against 6-hydroxydopamine-induced oxidative stress by increasing heme oxygenase-1 expression through an estrogen receptor-related PI3K/Akt/Nrf2-dependent pathway in human dopaminergic cells. Toxicol Appl Pharmacol 2010, 242:18-28. 10.1016/j.taap.2009.09.009, 19781563.
18. Radad K, Gille G, Moldzio R, Saito H, Ishige K, Rausch WD. Ginsenosides Rb1 and Rg1 effects on survival and neurite growth of MPP+-affected mesencephalic dopaminergic cells. J Neural Transm 2004, 111:37-45. 10.1007/s00702-003-0063-1, 14714214.
19. Radad K, Gille G, Moldzio R, Saito H, Rausch WD. Ginsenosides Rb1 and Rg1 effects on mesencephalic dopaminergic cells stressed with glutamate. Brain Res 2004, 1021:41-53. 10.1016/j.brainres.2004.06.030, 15328030.
20. Xu L, Chen WF, Wong MS. Ginsenoside Rg1 protects dopaminergic neurons in a rat model of Parkinson's disease through the IGF-I receptor signalling pathway. Br J Pharmacol 2009, 158:738-748. 10.1111/j.1476-5381.2009.00361.x, 2765594, 19703168.
21. Zou K, Zhu S, Meselhy MR, Tohda C, Cai S, Komatsu K. Dammarane-type Saponins from Panax japonicus and their neurite outgrowth activity in SK-N-SH cells. J Nat Prod 2002, 65:1288-1292. 10.1021/np0201117, 12350149.
22. Christensen LP. Ginsenosides chemistry, biosynthesis, analysis, and potential health effects. Adv Food Nutr Res 2008, 55:1-99.
23. Tansakul P, Shibuya M, Kushiro T, Ebizuka Y. Dammarenediol-II synthase, the first dedicated enzyme for ginsenoside biosynthesis, in Panax ginseng. FEBS Lett 2006, 580:5143-5149. 10.1016/j.febslet.2006.08.044, 16962103.
24. Wild Rose College and Wholistic Clinic. , http://www.wrc.net/wrcnet_content/herbalresources/materiamedica/materiamedica.aspx?mmid=15
25. McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 1999, 20:321-344. 10.1210/er.20.3.321, 10368774.
26. Katzenellenbogen BS, Choi I, Delage-Mourroux R, Ediger TR, Martini PG, Montano M, Sun J, Weis K, Katzenellenbogen JA. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology. J Steroid Biochem Mol Biol 2000, 74:279-285. 10.1016/S0960-0760(00)00104-7, 11162936.
27. Toran-Allerand CD. Minireview: A plethora of estrogen receptors in the brain: where will it end?. Endocrinology 2004, 145:1069-1074.
28. Dubal DB, Zhu H, Yu J, Rau SW, Shughrue PJ, Merchenthaler I, Kindy MS, Wise PM. Estrogen receptor alpha, not beta, is a critical link in estradiol-mediated protection against brain injury. Proc Natl Acad Sci USA 2001, 98:1952-1957. 10.1073/pnas.041483198, 29363, 11172057.
29. Mérot Y, Ferrière F, Debroas E, Flouriot G, Duval D, Saligaut C. Estrogen receptor alpha mediates neuronal differentiation and neuroprotection in PC12 cells: critical role of the A/B domain of the receptor. J Mol Endocrinol 2005, 35:257-267. 10.1677/jme.1.01826, 16216907.
30. Mérot Y, Ferrière F, Gailhouste L, Huet G, Percevault F, Saligaut C, Flouriot G. Different outcomes of unliganded and liganded estrogen receptor-alpha on neurite outgrowth in PC12 cells. Endocrinology 2009, 150:200-211.
31. Gollapudi L, Oblinger MM. Stable transfection of PC12 cells with estrogen receptor (ERalpha): protective effects of estrogen on cell survival after serum deprivation. J Neurosci Res 1999, 56:99-108. 10.1002/(SICI)1097-4547(19990401)56:1<99::AID-JNR13>3.0.CO;2-G, 10213481.
32. Mize AL, Shapiro RA, Dorsa DM. Estrogen receptor-mediated neuroprotection from oxidative stress requires activation of the mitogen-activated protein kinase pathway. Endocrinology 2003, 144:306-312. 10.1210/en.2002-220698, 12488359.
33. Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Oncogene 2007, 26:3100-3112. 10.1038/sj.onc.1210392, 17496909.
34. Zhang Y, Dong C. Regulatory mechanisms of mitogen-activated kinase signaling. Cell Mol Life Sci 2007, 64:2771-2789. 10.1007/s00018-007-7012-3, 17726577.
35. Wang YZ, Bonner JC. Mechanism of extracellular signal-regulated kinase (ERK)-1 and ERK-2 activation by vanadium pentoxide in rat pulmonary myofibroblasts. Am J Respir Cell Mol Biol 2000, 22:590-596.
36. Wang X, Martindale JL, Liu Y, Holbrook NJ. The cellular response to oxidative stress: influences of mitogen-activated protein kinase signalling pathways on cell survival. Biochem J 1998, 333:291-300. 1219585, 9657968.
37. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995, 270:1326-1331. 10.1126/science.270.5240.1326, 7481820.
38. Stanciu M, Wang Y, Kentor R, Burke N, Watkins S, Kress G, Reynolds I, Klann E, Angiolieri MR, Johnson JW, DeFranco DB. Persistent activation of ERK contributes to glutamate-induced oxidative toxicity in a neuronal cell line and primary cortical neuron cultures. J Biol Chem 2000, 275:12200-12206. 10.1074/jbc.275.16.12200, 10766856.
39. Subramaniam S, Zirrgiebel U, von Bohlen, Halbach O, Strelau J, Laliberté C, Kaplan DR, Unsicker K. ERK activation promotes neuronal degeneration predominantly through plasma membrane damage and independently of caspase-3. J Cell Biol 2004, 165:357-369. 10.1083/jcb.200403028, 2172179, 15123736.
40. Lu K, Liang CL, Liliang PC, Yang CH, Cho CL, Weng HC, Tsai YD, Wang KW, Chen HJ. Inhibition of extracellular signal-regulated kinases (ERK)1/2 provides neuroprotection in spinal cord ischemia/reperfusion injury in rats: relationship with the nuclear factor-κB-regulated antiapoptotic mechanisms. J Neurochem 2010, 114:237-246.
41. Satoh T, Nakatsuka D, Watanabe Y, Nagata I, Kikuchi H, Namura S. Neuroprotection by MAPK/ERK kinase inhibition with U0126 against oxidative stress in a mouse neuronal cell line and rat primary cultured cortical neurons. Neurosci Lett 2000, 288:163-166. 10.1016/S0304-3940(00)01229-5, 10876086.
42. Wang X, Wang H, Xu L, Rozanski DJ, Sugawara T, Chan PH, Trzaskos JM, Feuerstein GZ. Significant neuroprotection against ischemic brain injury by inhibition of the MEK1 protein kinase in mice: exploration of potential mechanism associated with apoptosis. J Pharmacol Exp Ther 2003, 304:172-178. 10.1124/jpet.102.040246, 12490588.
43. Lustig RH, Hua P, Yu W, Ahmad FJ, Baas PW. An in vitro model for the effects of estrogen on neurons employing estrogen receptor-transfected PC12 cells. J Neurosci 1994, 14:3945-3957.
44. Ossola B, Kääräinen TM, Raasmaja A, Männistö PT. Time-dependent protective and harmful effects of quercetin on 6-OHDA-induced toxicity in neuronal SH-SY5Y cells. Toxicology 2008, 250:1-8. 10.1016/j.tox.2008.04.001, 18756631.
45. Behl C, Skutella T, Lezoualc'h F, Post A, Widmann M, Newton CJ, Holsboer F. Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol Pharmacol 1997, 51:535-541.
46. Li N, Liu B, Dluzen DE, Jin Y. Protective effects of ginsenoside Rg2 against glutamate-induced neurotoxicity in PC12 cells. J Ethnopharmacol 2007, 111:458-463. 10.1016/j.jep.2006.12.015, 17257792.
47. Liu ZQ, Luo XY, Liu GZ, Chen YP, Wang ZC, Sun YX. In vitro study of the relationship between the structure of ginsenoside and its antioxidative or prooxidative activity in free radical induced hemolysis of human erythrocytes. J Agric Food Chem 2003, 51:2555-2558. 10.1021/jf026228i, 12696936.
48. Samukawa K, Suzuki Y, Ohkubo N, Aoto M, Sakanaka M, Mitsuda N. Protective effect of ginsenosides Rg(2) and Rh(1) on oxidation-induced impairment of erythrocyte membrane properties. Biorheology 2008, 45:689-700.
49. Lee Y, Jin Y, Lim W, Ji S, Choi S, Jang S, Lee S. A ginsenoside-Rh1, a component of ginseng saponin, activates estrogen receptor in human breast carcinoma MCF-7 cells. J Steroid Biochem Mol Biol 2003, 84:463-468. 10.1016/S0960-0760(03)00067-0, 12732291.
50. Kulich SM, Horbinski C, Patel M, Chu CT. 6-Hydroxydopamine induces mitochondrial ERK activation. Free Radic Biol Med 2007, 43:372-383. 10.1016/j.freeradbiomed.2007.04.028, 2023873, 17602953.
51. Lin E, Cavanaugh JE, Leak RK, Perez RG, Zigmond MJ. Rapid activation of ERK by 6-hydroxydopamine promotes survival of dopaminergic cells. J Neurosci Res 2008, 86:108-117. 10.1002/jnr.21478, 17847117.
52. Chan RY, Chen WF, Dong A, Guo D, Wong MS. Estrogen-like activity of ginsenoside Rg1 derived from Panax notoginseng. J Clin Endocrinol Metab 2002, 87:3691-3695. 10.1210/jc.87.8.3691, 12161497.
53. Cho J, Park W, Lee S, Ahn W, Lee Y. Ginsenoside-Rb1 from Panax ginseng C.A. Meyer activates estrogen receptor-alpha and -beta, independent of ligand binding. J Clin Endocrinol Metab 2004, 89:3510-3515. 10.1210/jc.2003-031823, 15240639.
54. Lau WS, Chan RY, Guo DA, Wong MS. Ginsenoside Rg1 exerts estrogen-like activities via ligand-independent activation of ERalpha pathway. J Steroid Biochem Mol Biol 2008, 108:64-71. 10.1016/j.jsbmb.2007.06.005, 17936617.
55. Lee YJ, Jin YR, Lim WC, Park WK, Cho JY, Jang S, Lee SK. Ginsenoside-Rb1 acts as a weak phytoestrogen in MCF-7 human breast cancer cells. Arch Pharm Res 2003, 26:58-63. 10.1007/BF03179933, 12568360.
56. Dhandapani KM, Brann DW. Protective effects of estrogen and selective estrogen receptor modulators in the brain. Biol Reprod 2002, 67:1379-1385. 10.1095/biolreprod.102.003848, 12390866.
57. Soldati F, Sticher O. HPLC separation and quantitative determination of ginsenosides from Panax ginseng, Panax quinquefolium and from ginseng drug preparations. 2nd communication. Planta Med 1980, 39:348-357. 10.1055/s-2008-1074929, 7413841.
58. Kang DI, Lee JY, Yang JY, Jeong SM, Lee JH, Nah SY, Kim Y. Evidence that the tertiary structure of 20(S)-ginsenoside Rg(3) with tight hydrophobic packing near the chiral center is important for Na(+) channel regulation. Biochem Biophys Res Commun 2005, 333:1194-1201. 10.1016/j.bbrc.2005.06.026, 15979567.
59. Liu J, Shiono J, Shimizu K, Yu H, Zhang C, Jin F, Kondo R. 20(R)-ginsenoside Rh2, not 20(S), is a selective osteoclastgenesis inhibitor without any cytotoxicity. Bioorg Med Chem Lett 2009, 19:3320-3323. 10.1016/j.bmcl.2009.04.054, 19428246.